PRGO — Perrigo Company plc

Summary of Perrigo (PRGO) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Full Year 2025 Results:
  • All-In Operating Income: Grew by 2%
  • All-In EPS: Increased by 7% to $2.75, aligning with revised guidance.
  • CORE Perrigo Operating Income: Up 7%, with CORE EPS up 14%.
• Q4 2025 Results:
  • CORE Organic Net Sales: Declined by 2%, despite strong market share gains.
  • CORE Operating Income: Decreased by $4 million (2%), resulting in CORE EPS of $0.76, down $0.02 from the prior year.
• Cash Position: Ended 2025 with $532 million in cash; Q4 operating cash flow was $175 million.

2. Strategic Updates and Business Highlights

• Three-S Plan: Continued progress in simplifying, streamlining, and strengthening the business, with a focus on stabilizing the store brand business and improving supply chain efficiency.
• Market Share Gains: Significant share gains in the U.S. OTC market and Europe, reversing years of decline.
• New Reporting Segments: Transitioning to new reporting segments (Self-care, Specialty Care, Infant Formula) starting Q1 2026 for enhanced transparency.
• Operational Enhancements: Implementing a two-year operational enhancement program expected to yield $80-$100 million in annualized savings.

3. Forward Guidance and Outlook

• 2026 Expectations:
  • CORE Perrigo Organic Net Sales Growth: Projected between -3.5% to +0.5%.
  • CORE EPS Guidance: Expected range of $2.25 to $2.55.
  • All-In EPS Guidance: Projected between $2.00 to $2.30, reflecting headwinds from the Infant Formula business.
  • Market Conditions: Anticipated improvement in the second half of 2026 as temporary market headwinds are expected to normalize.

4. Bad News, Challenges, or Points of Concern

• Infant Formula Business: Continued structural challenges impacting financials; expected to remain dilutive to earnings.
• Market Weakness: U.S. OTC market consumption down 5.1% over the last 13 weeks; retailers adjusting inventory levels due to soft demand.
• Goodwill Impairment: A noncash charge of $1.3 billion recorded, with potential additional impairment charges of up to $350 million expected in Q1 2026.
• Leverage Concerns: Net leverage ratio at 4x, slightly above projections; expected to remain flat year-over-year in 2026, impacting flexibility for reinvestment.

5. Notable Q&A Insights

• Market Recovery: Management expressed confidence in a second-half recovery driven by share growth, innovation, and improved demand generation.
• Operational Challenges: Under-absorption of plant capacity due to lower sales volumes is expected to impact margins in 2026 but is viewed as transitory.
• Infant Formula Strategy: Ongoing strategic review to assess options for the Infant Formula business, including potential partnerships or divestitures.
• Capital Allocation: Commitment to maintaining dividends while focusing on debt reduction and investing in innovation; proceeds from the Dermacosmetics sale will be used to reduce debt.

Overall, Perrigo is navigating a challenging market environment while making strides in operational efficiency and market share growth, with cautious optimism for recovery in the latter half of 2026.